[HTML][HTML] Comorbidities of atopic dermatitis—what does the evidence say?
Atopic dermatitis (AD) is a common disease that is associated with atopic and nonatopic
comorbidities. There has been a growing interest in this area of AD, because presence or …
comorbidities. There has been a growing interest in this area of AD, because presence or …
Disease modification in inflammatory skin disorders: opportunities and challenges
T Bieber - Nature Reviews Drug Discovery, 2023 - nature.com
Progress in understanding of the mechanisms underlying chronic inflammatory skin
disorders, such as atopic dermatitis and psoriasis vulgaris, has led to new treatment options …
disorders, such as atopic dermatitis and psoriasis vulgaris, has led to new treatment options …
OX40 in the pathogenesis of atopic dermatitis—a new therapeutic target
M Croft, E Esfandiari, C Chong, H Hsu… - American journal of …, 2024 - Springer
Atopic dermatitis (AD) is a chronic, heterogeneous, inflammatory disease characterized by
skin lesions, pruritus, and pain. Patients with moderate-to-severe AD experience chronic …
skin lesions, pruritus, and pain. Patients with moderate-to-severe AD experience chronic …
[PDF][PDF] Seronegative rheumatoid arthritis: one year in review 2023
L De Stefano, B D'Onofrio, S Gandolfo… - Clin Exp …, 2023 - clinexprheumatol.org
In the past 20 years, earlier diagnosis and more intensive management have considerably
improved the prognosis of rheumatoid arthritis (RA), with milder disease course achieved in …
improved the prognosis of rheumatoid arthritis (RA), with milder disease course achieved in …
Rapid reduction in Staphylococcus aureus in atopic dermatitis subjects following dupilumab treatment
Background Atopic dermatitis (AD) is an inflammatory disorder characterized by dominant
type 2 inflammation leading to chronic pruritic skin lesions, allergic comorbidities, and …
type 2 inflammation leading to chronic pruritic skin lesions, allergic comorbidities, and …
[HTML][HTML] Dupilumab-associated psoriasis and psoriasiform manifestations: a sco** review
Z Su, YP Zeng - Dermatology, 2023 - karger.com
Background: Dupilumab is the first approved IL-4Rα inhibitor for the treatment of atopic
dermatitis at present with good efficacy and safety. However, there have been several …
dermatitis at present with good efficacy and safety. However, there have been several …
Tumor necrosis factor-α inhibitor-related autoimmune disorders
L De Stefano, FB Pallavicini, E Mauric, V Piccin… - Autoimmunity …, 2023 - Elsevier
Biotechnological monoclonal antibodies and receptor antagonists capable of targeting
specific inflammatory actors, such as cytokines, cytokines receptors, co-stimulatory …
specific inflammatory actors, such as cytokines, cytokines receptors, co-stimulatory …
Biologic Medications for Severe Asthma: Implications for Understanding Pathogenic Heterogeneity and Endotypes
Asthma is a chronic inflammatory disease of the airways long known for phenotypic
heterogeneity. Phenoty** studies in asthma have led to a better characterization of …
heterogeneity. Phenoty** studies in asthma have led to a better characterization of …
Clinical phenotypes, serological biomarkers, and synovial features defining seropositive and seronegative rheumatoid arthritis: a literature review
Rheumatoid arthritis (RA) is a chronic autoimmune disorder which can lead to long-term
joint damage and significantly reduced quality of life if not promptly diagnosed and …
joint damage and significantly reduced quality of life if not promptly diagnosed and …
[HTML][HTML] Use of Mendelian randomization to assess the causal status of modifiable exposures for rheumatic diseases
The explosion in Mendelian randomization (MR) publications is hard to ignore and shows
no signs of slowing. Clinician readers, who may not be familiar with jargon-ridden methods …
no signs of slowing. Clinician readers, who may not be familiar with jargon-ridden methods …